Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

InMed Pharmaceuticals (INM) Notes Payables (2021 - 2022)

InMed Pharmaceuticals has reported Notes Payables over the past 2 years, most recently at $29312.0 for Q1 2022.